Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1138 • ACR Convergence 2023
Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies
Cristiana Sieiro Santos¹, Jose Luis Tandaipan², Anais Mariscal², Luis Sainz-Comas², Helena Codes², Patricia Moya², Berta Paula Magallares-Lopez³, Laura Martínez Martínez², Ana Milena Millán Arciniegas², Hye Sang Park², César Díaz-Torné², Ana Laíz Alonso², Susana Fernández², Sandra Ros², Hector Corominas⁴, Elvira Díez Álvarez⁵ and Iván Castellvi², ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ³Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ⁵CAULE, León, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful…
Abstract Number: 1597 • ACR Convergence 2023
Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus
Wangbin Ning, Gary Gilkeson and Wei Jiang, Medical University of South Carolina, Charleston, SC
Background/Purpose: There is an intricate interplay between the microbiome and the immune response impacting the development of normal immunity and autoimmunity. However, we do not…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 2578 • ACR Convergence 2023
Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles
Jenny Wei¹, Mark Tarnopolsky², Marie Hudson³, Ross Mitchell⁴, Katherine Buhler⁵, Antoine Dufour⁶, Luiz de Almeida⁶, Paul R. Fortin⁷, Eric Boilard⁸, Yann Becker⁸, Erin Hatcher², Mei Feng Zhang⁶, Marvin Fritzler⁶ and May Choi⁶, ¹University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁸Université Laval, Quebec City, QC, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…
Abstract Number: 0253 • ACR Convergence 2023
Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity
Ruoning Ni¹ and Petar Lenert², ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Anti-ribonucleoprotein (RNP) and anti-Sm/RNP common motif antibodies play a critical role in diagnosing patients with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)…
Abstract Number: 0665 • ACR Convergence 2023
A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody
Mridula Dilip¹, Maureen Laffoon², Yongseok Park³, Robert Lafyatis⁴, Thomas Medsger⁵, Virginia Steen⁶, Leigh Freno² and Robyn Domsic⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh School of Medicine, Verona, PA, ⁶Georgetown University School of Medicine, Washington, DC
Background/Purpose: U2RNP is a spliceosome-associated autoantibody that has in prior case reports presented with scleroderma with myositis (SSc/PM)and SLE overlap. Autoantibodies are growing in prognostic…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1972 • ACR Convergence 2023
Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Christina Charles-Schoeman¹, Joachim Schessl², Rohit Aggarwal³ and and the ProDERM investigators⁴, ¹UCLA Medical Center, Santa Monica, CA, ²Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
Abstract Number: 067 • 2023 Pediatric Rheumatology Symposium
Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis
Yike Jiang, Alexander Sandweiss, Timothy Erickson, Eyal Muscal and Kristy Murray, Baylor College of Medicine, Houston, TX
Background/Purpose: The discovery of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis heralded a new class of neuropsychiatric illnesses mediated by autoantibodies, known collectively as autoimmune encephalitis. The clinical…
Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Yiressy Pina¹, Dawn Janysek¹, Danielle Guffey², Maria Pereira Palacios³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0166 • ACR Convergence 2022
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato¹, ¹Tokai University School of Medicine, Isehara Kanagawa, Japan, ²Tokai University School of Medicine, sagamihara-city, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM), many kinds of autoantibodies are often detected and associated with each clinical phenotype. Recently, autoantibody against transcription factor Sp4…
Abstract Number: 0683 • ACR Convergence 2022
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
Irene Cecchi¹, Massimo Radin², Silvia Grazietta Foddai², Maria Laura Bertolaccini³, Danieli De Andrade⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul Fortin¹⁰, Chary Lopez-Pedrera¹¹, Zhouli Zhang¹², Tatsuya Atsumi¹³, Guilherme de Jesus¹⁴, Hannah Cohen¹⁵, Nina Kello¹⁶, Ware Branch¹⁷, Denis Wahl¹⁸, Laura Andreoli¹⁹, Esther Rodriguez²⁰, Michelle Petri²¹, Megan R.W. Barber²², Ricard Cervera²³, Jason Knight²⁴, Bahar Artim-Esen²⁵, Rohan Willis²⁶, Guillermo Pons-Estel²⁷, Doruk Erkan²⁸ and Savino Sciascia¹, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Athens, Athens, Greece, ⁶University of Padova, Padova, Italy, ⁷University of the Basque Country, Barakaldo, Spain, ⁸New York University School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec Université Laval, Québec, QC, Canada, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Beijing Medical University, Beijing, China, ¹³Hokkaido University, Sapporo, Japan, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵University College London, London, United Kingdom, ¹⁶Northwell Health, New York, NY, ¹⁷University of Utah Health, Salt Lake City, ¹⁸Nancy University Hospital, Nancy, France, ¹⁹University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Baltimore, MD, ²²University of Calgary, Calgary, AB, Canada, ²³University of Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶University of Texas, Galveston, TX, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁸Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: APS ACTION is an international Clinical Database and Repository of persistently antiphospholipid antibody (aPL)-positive subjects, collecting demographic, medical history, and aPL data.This study focused…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].